Investors demanded more clarity from German healthcare group Fresenius SE regarding its intentions to relinquish strategic control over dialysis group Fresenius Medical Care AG (NYSE:FMS).  The investors’ call for transparency comes in the wake of Fresenius’s recent deconsolidation of Fresenius Medical Care, where the company still retains a 32% stake. Fresenius Medical Care faced significant challenges during the COVID-19 pandemic, including a higher mortality rate among dialysis patients and a shortage of nursing staff.  “The volatility at Fresenius Medical Care seems to repeatedly overshadow the recent positive operating developments at Fresenius and is also deterring many potential shareholders from investing in Fresenius,” Reuters noted, citing Hendrik ...